CME/CE Podcast: Emerging Options for Managing Hyperkalemia in Challenging Patients

For more information regarding this CME/CE activity and to complete the CME/CE requirements and claim credit for this activity, visit:https://www.mycme.com/courses/management-of-hyperkalemia-in-high-risk-patients-8850Featuring faculty George Bakris, MD, moderated by Gregg Sherman, MD.SummaryHyperkalemia is a common condition in certain patient populations and can increase risks for hospitalizations and mortality. The limitations of traditional treatment approaches make management of high-risk patients challenging, particularly in those with chronic kidney disease (CKD), heart failure (HF), and hypertension. However, new and emerging treatment options are available for the management of hyperkalemia and may improve outcomes in these patients.In this second of two podcast episodes, Dr. George Bakris and Dr. Gregg Sherman discuss new and emerging treatment options for the management of hyperkalemia, and how to incorporate these therapies most effectively for patients with CKD, HF, and hypertension. This podcast was recorded and is being used with the permission of the presenters.This CME/CE podcast is available for credit on myCME. Click the button on the right to listen now.Learning ObjectivesUpon completion of this activity, learners should be able to:Incorporate current and emerging therapies into the management of hyperkalemia in patients with CKD, HF, and hypertension based on recent clinical trial dataThis activity is accredited for CME/CE Credit.The National Association for Continuing Education is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.The National Association for Continuing Education designates this enduring material for a maximum of 0.25 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.National Association for Continuing Education is accredited by the American Association of Nurse Practitioners as an approved provider of nurse practitioner continuing education. Provider number: 121222. This activity is approved for 0.25 contact hours (which includes 0.25 hours of pharmacology).Summary of Individual DisclosuresGeorge Bakris: has disclosed the following financial relationships:Consultant: Bayer (Diabetic Kidney Disease), KBP BioSciences (Hypertension), Ionis (Hypertension), Alnylam (Hypertension), AstraZeneca (Hyperkalemia), Novo Nordisk (Diabetic Kidney Disease), Janssen (Hypertension), inRegen (Kidney Disease)Contracted Research: KBP BioSciences (Hypertension)Angela Golden has disclosed the following financial relationships:Consultant: SetPoint (Obesity), WW (Obesity)Advisor: Currax (Obesity), Genesis (Obesity), Lilly (Obesity), Novo Nordisk (Obesity), (Obesity), Acela (Hypothyroidism)Speaker: Currax, Novo Nordisk (Obesity)Receipt of Royalty: Amazon (fiction books), Springer (obesity book)Faculty, planners, guest patient(s) (if applicable), and moderators for this educational activity not listed in the Summary of Individual Disclosures above have no relevant financial relationship(s) to disclose with ineligible companies whose primary business is producing, marketing, selling, re-selling, or distributing healthcare products used by or on patients.Disclosure of Commercial SupportThis educational activity is supported by an independent educational grant from AstraZeneca Pharmaceuticals.Please visit  http://naceonline.com to engage in more live and on demand CME/CE content.